BMC Cancer

Table 1 Target volume doses for the TROG 17.03 LARK clinical trial. TD = Target Dose (prescribed dose). RVR = Remaining Volume at Risk

From: Study protocol of the LARK (TROG 17.03) clinical trial: a phase II trial investigating the dosimetric impact of Liver Ablative Radiotherapy using Kilovoltage intrafraction monitoring

LARK Target Volume Doses
Standardised Name	Constraint	Per Protocol		Minor Variation		Major Variation
Standardised Name	Constraint	PTVs around GTVs	PTVs around Non-GTV CTVs^a	PTVs around GTVs	PTVs around Non-GTV CTVs^a	PTVs around GTVs	PTVs around Non-GTV CTVs^a
GTV	D100%	≥100% of the TD		95–100% of the TD		≤95% of the TD
PTV	Dmax (0.03 cc)	120–140% of the TD		140–150% of the TD or 110–120% of the TD		≥150% of the TD or ≤ 110% of the TD
PTV	D95%	95–105% of the TD		90–95% or 105–110% of the TD, and > 25 Gy	85–95% or 105–115% of the TD, and > 25 Gy	≤90% or ≥110% of the TD, or ≤ 25 Gy	≤85% or ≥115% of the TD, or ≤ 25Gy
RVR	Dmax (0.03 cc)	≤120% of the TD		–		≥120% of the TD

^a Non-GTV CTVs represents regions at high risk for microscopic disease, including non-tumour vascular thrombi, prior TACE sites, or adjacent RFA or other ablation sites. Treatment of these high-risk sites are permitted

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com